<DOC>
	<DOCNO>NCT01055028</DOCNO>
	<brief_summary>This open-label , single-arm , multi-center , Phase 2 study Paclitaxel combination Bevacizumab patient Unresectable Metastatic Angiosarcoma . The study aim determine safety effectiveness combine two drug Paclitaxel Bevacizumab treatment Angiosarcoma remove surgery , spread part body . The primary objective evaluate 4month non progression rate . The secondary objective evaluate overall response rate 3rd 6th cycle , median duration response , 6th 12th month survival , toxicity Paclitaxel Bevacizumab combination , toxicity maintenance Bevacizumab collect paraffin-embedded tumor block angiogenesis marker tissue microarray .</brief_summary>
	<brief_title>Paclitaxel + Bevacizumab ( AvastinÂ® ) Treatment Metastatic Unresectable Angiosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Baseline measurement evaluation must obtain within 4 week registration study . Abnormal PET scan constitute evaluable disease , unless verify CT scan appropriate imaging . Patient must least one objective measurable disease parameter RECIST criterion . Patients must unresectable locally advanced metastatic angiosarcoma . Patients must &lt; = 2 prior chemotherapeutic regimen angiosarcoma . No prior paclitaxel , docetaxel , bevacizumab angiosarcoma . ( Previous paclitaxel docetaxel allow give angiosarcoma 12 month elapse since last dose ) Patients must evidence active malignancy carcinomas insitu cervix basal cell carcinoma skin within 6 month prior registration . Patients history deep venous thrombosis pulmonary embolism must receive stable dose anticoagulation therapy least 2 week prior registration . Patients must use antiplatelet drug , ticlopidine , clopidogrel , cilostazol , study within 7 day prior registration . The use aspirin nonsteroidal antiinflammatory drug ( NSAID ) allow . Patients must ECOG performance status 02 . Patients must adequate organ function evidence follow laboratory study ( within 2 week prior registration ) : Serum creatinine ( &lt; = 2.0 mg/dl ) Total bilirubin &lt; = 2.0 x ULN SGOT ( AST ) &lt; 2 x ULN . If document hepatic involvement , total bilirubin &lt; = 3 x ULN , AST &lt; = 5 x ULN . Absolute neutrophil count &gt; = 1500/mm3 platelet count &gt; 100,000/mm3 . PT , INR , PTT &lt; = 1.5 x normal . Patients must active infection require parental antibiotic . Patients must know HIV infection due increase risk infection . Patients must leave ventricular ejection fraction &gt; = 50 % eligible . Patients must age &gt; = 13 year . Women must pregnant breast feeding due potential harmful effect fetus/baby . Women childbearing potential must HCG within 2 week prior registration . Women childbearing potential sexually active male must strongly advise use accept effective method contraception . Inability comply study and/or followup procedure Life expectancy le 12 week Current , recent ( within 4 week first infusion study ) , plan participation another experimental drug study Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix D ) History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Known CNS disease , except treat brain metastasis Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis ( &gt; = 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria demonstrate UPC ratio &gt; = 1.0 screen Known hypersensitivity component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>